Estriol

Q: Is estriol the same as estradiol?

No. Both are estrogens the body makes, but estriol is a weak one and a natural breakdown product of estradiol. UK product information describes it as short-acting, with blood levels close to the postmenopausal range when the vaginal cream is used twice a week.

Q: Does vaginal estriol prevent recurrent urinary tract infections?

In a 1993 trial of 93 women, estriol cream cut infections to 0.5 from 5.9 episodes per patient-year on placebo, and a 2024 gel trial lowered the rate by 26%. Twice-weekly pessaries allowed more infections than daily nitrofurantoin in a 2003 trial. A clinician decides which fits.

Q: Is estriol safer than other estrogens?

No trial has shown that. Oral estriol taken for five years or more was linked to three times the odds of endometrial cancer in a Swedish study, and the UK labels carry the same contraindications as other estrogens. ACOG says claims that bioidentical hormones are safer lack evidence.

Q: Can women with breast cancer use vaginal estriol?

UK labels list known, past or suspected breast cancer as a contraindication. A 12-week trial in 61 women on aromatase inhibitors found a 50-microgram gel left estradiol and estrone mostly undetectable. The Menopause Society says safety data after breast cancer are insufficient and that the oncologist's view counts.

Q: Does estriol need a progestogen?

UK product information does not recommend one with twice-weekly vaginal estriol, but it limits daily dosing to four weeks at most. For oral estriol, a Swedish study linked long-term use to endometrial cancer and suggested considering a progestogen. A clinician decides.

Q: Is a hormone-free moisturiser an alternative?

In a 2022 open-label trial of 172 women, a hormone-free cream was non-inferior to 0.1% estriol cream for dryness, itching and burning after 43 days; women with severe impact on daily life did better on estriol. The Menopause Society says non-hormone products relieve most mild symptoms.

Q: Does estriol help multiple sclerosis?

In a phase 2 trial, 164 women on glatiramer acetate had 0.25 versus 0.37 relapses a year with oral estriol 8 mg added (rate ratio 0.63, 95% CI 0.37 to 1.05). The authors said a phase 3 trial is needed to confirm it.

Q: What does bioidentical mean for estriol?

The FDA calls bioidentical a marketing term with no medical or scientific basis when used to imply a benefit. The estriol in UK creams is chemically identical to the body's own, which says nothing about whether a product is safe or effective. A 2021 review calls custom-mixed versions basically unstudied and inconsistently labeled.

Brand names: Gynest. Also called oestriol, E3, estriol cream, estriol vaginal gel, bioidentical estriol.

Estrogen (estriol, a weak estrogen) 7 graded human studies Last checked Oct 23, 2026

The short answer

From 14 sources

Estriol is a weak estrogen, a natural breakdown product of estradiol whose levels rise in pregnancy. As a medicine it is mostly a vaginal cream or gel for menopausal dryness and irritation. Small trials also tested it against recurrent urinary infections and, taken by mouth, in multiple sclerosis. Long-term oral use was linked to endometrial cancer.

Key facts

Main use: Vaginal atrophy after menopause (UK labels)^3,4
UK label dose: 0.5 mg in the vagina daily for up to 4 weeks, then a maintenance dose such as twice a week³
Molecule: Chemically identical to the estriol the body makes; a weak estrogen⁴
Blood levels: Twice-weekly vaginal use keeps estriol close to the postmenopausal range³
Allergy note: Gynest cream contains arachis (peanut) oil⁴
Longest trial: 24 months: 8 mg by mouth daily, in multiple sclerosis¹²

Which estriol products are approved, and for what?

No estriol product is FDA-approved: the FDA said in 2008 that estriol is not a component of any FDA-approved drug and that its safety and effectiveness are unknown. In the US it reaches patients through compounding pharmacies. In the UK, estriol vaginal creams are licensed prescription-only medicines for menopausal vaginal atrophy.

Status by form

3 forms

Estriol products and their regulatory status
Form	Status	Approved for	Boxed warning
Estriol creams and capsules made to order (US), alone or with estradiol	Compounded by pharmacies; no FDA-approved product contains estriol. The FDA warned seven pharmacies in 2008 that their safety and superiority claims were unsupported^1,2	None	No FDA label
Estriol 1 mg/g vaginal cream (UK)	Licensed prescription-only medicine in the UK³	Vaginal atrophy from estrogen deficiency after menopause; before and after vaginal surgery	Not used in UK product information
Estriol 0.01% vaginal cream (UK)Gynest	Licensed prescription-only medicine in the UK⁴	Atrophic vaginitis and kraurosis after menopause; vulval itching and painful sex from vaginal atrophy	Not used in UK product information

What is estriol and how does it work?

Estriol is a weak estrogen, a natural breakdown product of estradiol, and its levels rise in pregnancy. Applied in the vagina it binds estrogen receptors in the thinned lining after menopause, rebuilding the epithelium so lactobacilli can return and the pH can fall back to acidic. It is short-acting and leaves the body mainly in urine.

How it works

Estrogen (estriol, a weak estrogen)

Estriol binds estrogen receptors in the female genital tract. In vaginal atrophy it restores the thinned lining, which lets lactobacilli return and the vaginal pH fall back to an acidic level: in a 1993 trial lactobacilli reappeared in 61% of women on estriol and none on placebo, and pH fell from 5.5 to 3.8. It is short-acting and leaves the body mainly in urine.^4,3,5

What doses are on the label and in studies?

UK product information sets 0.5 mg estriol in the vagina daily for up to four weeks, then a gradual step down to a maintenance dose such as twice a week. Trials in women on aromatase inhibitors used a 50-microgram gel daily for three weeks, then twice weekly. A multiple sclerosis trial used 8 mg by mouth daily.

Label and study amounts, not a dose for you. A prescriber decides whether and how much; these show what the labels print and what trials used.

Doses by use

6 rows

Estriol doses as labelled or studied
Use	Form	Amount and schedule	Basis
Vaginal atrophy after menopause	Estriol 1 mg/g vaginal cream (UK)	One applicator (0.5 g cream, 0.5 mg estriol) daily for the first weeks, at most 4 weeks, then a gradual reduction to a maintenance dose such as one application twice a week³	Label
Before and after vaginal surgery	Estriol 1 mg/g vaginal cream (UK)	0.5 mg daily starting 2 weeks before the operation; after at least 2 weeks' break, 0.5 mg twice a week³	Label
Atrophic vaginitis, vulval itching, painful sex	Gynest 0.01% vaginal cream (UK)	One applicator (5 ml, 0.5 mg estriol) daily, then one applicator twice a week once the lining has recovered⁴	Label
Vaginal atrophy during aromatase inhibitor therapy (trial)	Estriol 0.005% vaginal gel	1 g gel (50 micrograms estriol) daily for 3 weeks, then twice weekly to week 12⁸	Study
Preventing recurrent urinary infections (trial)	Estriol vaginal pessary	0.5 mg twice weekly for 9 months⁶	Study
Relapsing-remitting multiple sclerosis, with glatiramer acetate (trial)	Oral estriol	8 mg daily for 24 months¹²	Study

What is estriol combined with?

With low-dose vaginal estriol twice a week, UK product information does not recommend adding a progestogen, because blood levels stay near the postmenopausal range. Oral estriol is different: a Swedish study linked years of use to endometrial cancer and suggested considering a progestogen. Trials have also paired vaginal estriol with aromatase inhibitors and oral estriol with glatiramer acetate.

Estriol and a progestogen

Estrogen alone can overgrow the uterine lining.

UK product information does not recommend adding a progestogen to twice-weekly vaginal estriol, because blood levels stay near the postmenopausal range, and it limits the daily 0.5 mg dose to 4 weeks at most. For oral estriol 1 to 2 mg a day, a Swedish case-control study found a raised endometrial cancer risk and said a progestagen should be considered.^3,11

Checked: Bleeding or spotting at any time is investigated.

Vaginal estriol during aromatase inhibitor therapy

Aromatase inhibitors for breast cancer often cause vaginal dryness.

In a 12-week placebo-controlled trial of 61 women on nonsteroidal aromatase inhibitors, a 0.005% gel improved dryness, pH and sexual function scores; estradiol and estrone stayed mostly undetectable and FSH and LH stayed in the postmenopausal range. UK labels list past breast cancer as a contraindication, and The Menopause Society says data are insufficient to confirm vaginal estrogen safety after breast cancer.^8,9,3,13

Checked: The trial measured blood estrogens, FSH and LH at weeks 1, 3, 8 and 12.

Oral estriol with glatiramer acetate (multiple sclerosis)

Multiple sclerosis relapses fall during pregnancy, when estriol is high.

In a 24-month phase 2 trial of 164 women, estriol 8 mg a day added to glatiramer acetate 20 mg gave 0.25 relapses a year versus 0.37 with glatiramer and placebo (rate ratio 0.63, 95% CI 0.37 to 1.05). That met the trial's preset threshold (p below 0.10), and the authors called for a phase 3 trial.¹²

Checked: The trial checked mammograms, uterine ultrasound and endometrial biopsies and found no differences between groups.

How does estriol relate to fertility and pregnancy?

Estriol products are not indicated in pregnancy, and UK product information says treatment stops if pregnancy occurs. Estriol passes into breast milk and may reduce milk production. In premenopausal women with multiple sclerosis taking 8 mg a day by mouth, irregular periods occurred in 23% of women versus 4% on placebo over two years.

Fertility, pregnancy and breastfeeding

Pregnancy: UK labels say estriol is not indicated in pregnancy and treatment is withdrawn at once if pregnancy occurs; most studies of accidental exposure found no harm to the fetus.^3,4
Breastfeeding: Estriol is excreted in breast milk and may decrease milk production; it is not indicated during lactation.³
Periods before menopause: In women aged 18 to 50 taking 8 mg a day by mouth, irregular periods occurred in 23% versus 4% on placebo.¹²

What gets checked during treatment?

UK product information calls for review of vaginal estrogen use at least once a year, because endometrial safety beyond a year is uncertain. Bleeding or spotting at any point is investigated, which may include an endometrial biopsy. Breast checks and mammography follow usual screening practice. How often anything is checked is a clinician's decision.

Monitoring

3 checks

What is monitored on estriol
Check	When	Why
Whether to continue	At least once a year^3,4	Endometrial safety of vaginal estrogen used for more than a year is uncertain
Bleeding or spotting	Whenever it happens during treatment³	It may need an endometrial biopsy to rule out cancer
Breast checks and mammography	As in usual screening practice³	Breast changes are reported; the label adapts checks to the individual woman

What does the research show?

The data are small randomized trials. Vaginal estriol cut recurrent urinary infections against placebo in two trials but allowed more infections than daily nitrofurantoin in a third. A 50-microgram gel relieved vaginal atrophy in breast cancer survivors on aromatase inhibitors. Long-term oral estriol was linked to endometrial cancer in a Swedish case-control study.

Every graded row

7 rows from 7 studies

Form tested

Showing 7 of 7 outcomes. Human trials only.

Grade CEndometrial cancer with oral estriolUterine liningWorsenedObservational
n 4,157 · 1999

Odds ratio 3.0 (95% CI 2.0 to 4.4) for endometrial cancer and 8.3 (4.0 to 17.4) for atypical hyperplasia; the excess faded quickly after stopping. Vaginal low-potency estrogen showed only weak associations.

Design: Observational, n = 4,157, 1999
Population: Swedish postmenopausal women: 789 endometrial cancer cases and 3,368 controls
Form: Oral estriol
Dose: 1 to 2 mg daily
Duration: 5 years or more vs never
Source: Reference 11 · PubMed 10359406 (opens PubMed)

Grade CVaginal dryness symptoms vs a hormone-free creamVaginal atrophyNo effectOpen-label trial
n 172 · 2022

Symptom scores fell 5.4 points on estriol and 5.0 on the hormone-free cream, which was non-inferior; women with severe impact on daily life did better on estriol. Four of six authors were employees of Dr. August Wolff GmbH.

Design: Open-label trial, n = 172, 2022
Population: Postmenopausal women with vulvovaginal dryness
Form: Estriol 0.1% vaginal cream
Dose: Estriol cream vs hormone-free moisturising cream
Duration: 43 days
Source: Reference 10 · PubMed 35551533 (opens PubMed)

Grade CRecurrent urinary infections vs nitrofurantoinUrinary infectionsWorsenedRCT
n 171 · 2003

124 infections on estriol vs 48 on nitrofurantoin (P=.0003); estriol did not restore lactobacilli or lower vaginal pH in this trial.

Design: RCT, n = 171, 2003
Population: Postmenopausal women with recurrent urinary tract infections
Form: Estriol vaginal pessary
Dose: 0.5 mg twice weekly vs nitrofurantoin 100 mg daily
Duration: 9 months
Source: Reference 6 · PubMed 12766829 (opens PubMed)

Grade CMultiple sclerosis relapsesMultiple sclerosisImprovedRCT
n 164 · 2016

0.25 vs 0.37 confirmed relapses a year (rate ratio 0.63, 95% CI 0.37 to 1.05; p=0.077, inside the trial's preset p<0.10 threshold). A phase 2 result; the authors called for a phase 3 trial.

Design: RCT, n = 164, 2016
Population: Women aged 18 to 50 with relapsing-remitting multiple sclerosis
Form: Oral estriol with glatiramer acetate
Dose: 8 mg daily plus glatiramer acetate 20 mg daily, vs placebo plus glatiramer
Duration: 24 months
Source: Reference 12 · PubMed 26621682 (opens PubMed)

Grade CRecurrent urinary tract infectionsUrinary infectionsImprovedRCT
n 108 · 2024

Infection rate was 26% lower: 32.34 vs 43.76 new cases per 100 woman-years (RR 0.74, P<0.001), with lower vaginal pH. Four authors were employees of ITF Research Pharma.

Design: RCT, n = 108, 2024
Population: Postmenopausal women with genitourinary syndrome of menopause
Form: Estriol 0.005% vaginal gel
Dose: 1 g gel (50 micrograms estriol) vs moisturising gel without estriol
Duration: 24 weeks
Source: Reference 7 · PubMed 39388913 (opens PubMed)

Grade CRecurrent urinary tract infectionsUrinary infectionsImprovedRCT
n 93 · 1993

Infections fell to 0.5 vs 5.9 episodes per patient-year on placebo (P<0.001); lactobacilli returned in 61% vs none and pH fell from 5.5 to 3.8. Only 36 of 50 and 24 of 43 women completed follow-up.

Design: RCT, n = 93, 1993
Population: Postmenopausal women with recurrent urinary tract infections
Form: Intravaginal estriol cream
Dose: Estriol cream vs placebo cream
Duration: 8 months
Source: Reference 5 · PubMed 8350884 (opens PubMed)

Grade CVaginal atrophy during aromatase inhibitor therapyVaginal atrophyImprovedRCT
n 61 · 2020

Improved vaginal maturation, pH, dryness and sexual function scores vs placebo (50 vs 11 women); estradiol and estrone stayed mostly undetectable and FSH and LH stayed in the postmenopausal range.

Design: RCT, n = 61, 2020
Population: Postmenopausal women with early breast cancer on nonsteroidal aromatase inhibitors
Form: Estriol 0.005% vaginal gel
Dose: 50 micrograms daily for 3 weeks, then twice weekly
Duration: 12 weeks
Source: Reference 8 · PubMed 32049923 (opens PubMed)

What are the side effects and risks?

UK labels list application-site irritation and itching, breast discomfort and genital burning. They say the clot, stroke and cancer risks of systemic hormone therapy apply to a lesser extent to low-dose vaginal estriol. Oral estriol taken for five years or more tripled the odds of endometrial cancer in one study. Bleeding during treatment is investigated.

Regulatory status. No estriol product is FDA-approved; in the US estriol comes from compounding pharmacies, while in the UK estriol vaginal creams are licensed prescription-only medicines with the full estrogen contraindication list.^1,2,3,4

Side effects in estriol trials, compared with placebo, and on the UK label

Trial rates are estriol vs placebo; label items have no reported rate

Common side effects of estriol
Side effect	Rate: drug vs placebo
Stopping because of side effects (vaginal cream)	28% vs 17% on placebo⁵
Irregular periods (8 mg by mouth)	23% vs 4% on placebo¹²
Serious adverse events (8 mg by mouth)	10% vs 13% on placebo¹²
Vaginal infections (8 mg by mouth)	1% vs 11% on placebo (fewer on estriol)¹²
Application-site irritation and itching	Not reported³
Breast discomfort or pain	Not reported³
Genital or vulvovaginal burning	Not reported³

Warnings on the label

Endometrial cancer with long-term oral use: Oral estriol 1 to 2 mg a day for five years or more was linked to an odds ratio of 3.0 for endometrial cancer and 8.3 for atypical hyperplasia; the excess faded quickly after stopping, and vaginal use showed only weak links.^11,3
Bleeding or spotting: Bleeding at any time during treatment is investigated, which may include an endometrial biopsy.³
Clots, stroke and breast cancer: UK labels say these risks of systemic hormone therapy apply to a lesser extent to low-dose vaginal estriol, but are weighed with long-term or repeated use.^3,4
Reasons the labels give to stop: Jaundice or worsening liver function, a significant rise in blood pressure, a new migraine-type headache, pregnancy, or a newly found contraindication.^3,4

Who should not use it (label contraindications)

Known, past or suspected breast cancer; known or suspected estrogen-dependent cancer such as endometrial cancer; undiagnosed genital bleeding; untreated endometrial hyperplasia; past or current deep vein thrombosis or pulmonary embolism; known clotting disorders; active or recent angina or heart attack; acute liver disease or liver tests that have not returned to normal; porphyria; allergy to estriol or an ingredient.^3,4

What does estriol interact with?

UK product information names enzyme-inducing drugs, such as carbamazepine, phenytoin, rifampicin and St John's wort, as able to speed estrogen breakdown and weaken the effect, though vaginal estriol may be less affected. One label says the cream can damage rubber condoms and diaphragms, and that estrogen may lower lamotrigine levels.

Interactions

4 agents

Published interactions with estriol
With	What happens	Evidence
Enzyme-inducing drugscarbamazepine, phenytoin, phenobarbital, rifampicin, rifabutin, nevirapine, efavirenz	May speed estrogen breakdown, weakening the effect and changing the bleeding pattern; vaginal estriol avoids first-pass liver metabolism and may be less affected.^3,4	Drug label
St John's wort	Named in both UK labels as able to induce estrogen metabolism and weaken the effect.^3,4	Drug label
Lamotrigine	Estrogen-containing contraceptives lower lamotrigine levels; the Gynest label expects a similar effect with estrogen hormone therapy, which may reduce seizure control.⁴	Drug label
Corticosteroids, theophyllines, succinylcholine, troleandomycin	The Aspen label says estriol may increase their effects.³	Drug label

Check your own medicines and supplements in the Interaction map: every edge is sourced, and nothing you enter leaves your browser.

How do the options compare?

Against placebo, vaginal estriol lowered urinary infections in a 1993 cream trial (0.5 vs 5.9 episodes per patient-year) and a 2024 gel trial. Against daily nitrofurantoin, twice-weekly estriol pessaries allowed more infections (124 vs 48 episodes). A hormone-free moisturiser matched estriol cream on dryness symptoms in a 2022 open-label trial.

Vaginal estriol against placebo and alternatives

Vaginal estriol against placebo and alternatives
	Estriol	Comparison	Trial
Urinary infections vs placebo cream	0.5 episodes per patient-year	5.9 on placebo	1993, 93 women, 8 months
Urinary infections vs placebo gel	32.3 per 100 woman-years	43.8 on placebo gel	2024, 108 women, 24 weeks
Urinary infections vs nitrofurantoin	124 episodes (0.5 mg pessary twice weekly)	48 episodes (100 mg daily)	2003, 171 women, 9 months
Dryness symptom score vs hormone-free cream	Fell 5.4 points (6.0 to 0.6)	Fell 5.0 points (6.1 to 1.1); non-inferior	2022, 172 women, 43 days, open-label

Which tools and services help with this?

Getting a prescription

CompareCompare menopause HRT telehealth servicesPrices, what each service prescribes and which states they cover, from our telehealth compare engine.

Frequently asked questions

Common questions

8 answers

Is estriol the same as estradiol?

No. Both are estrogens the body makes, but estriol is a weak one and a natural breakdown product of estradiol. UK product information describes it as short-acting, with blood levels close to the postmenopausal range when the vaginal cream is used twice a week.^4,3

Does vaginal estriol prevent recurrent urinary tract infections?

In a 1993 trial of 93 women, estriol cream cut infections to 0.5 from 5.9 episodes per patient-year on placebo, and a 2024 gel trial lowered the rate by 26%. Twice-weekly pessaries allowed more infections than daily nitrofurantoin in a 2003 trial. A clinician decides which fits.^5,7,6

Is estriol safer than other estrogens?

No trial has shown that. Oral estriol taken for five years or more was linked to three times the odds of endometrial cancer in a Swedish study, and the UK labels carry the same contraindications as other estrogens. ACOG says claims that bioidentical hormones are safer lack evidence.^11,3,2

Can women with breast cancer use vaginal estriol?

UK labels list known, past or suspected breast cancer as a contraindication. A 12-week trial in 61 women on aromatase inhibitors found a 50-microgram gel left estradiol and estrone mostly undetectable. The Menopause Society says safety data after breast cancer are insufficient and that the oncologist's view counts.^3,8,9,13

Does estriol need a progestogen?

UK product information does not recommend one with twice-weekly vaginal estriol, but it limits daily dosing to four weeks at most. For oral estriol, a Swedish study linked long-term use to endometrial cancer and suggested considering a progestogen. A clinician decides.^3,11

Is a hormone-free moisturiser an alternative?

In a 2022 open-label trial of 172 women, a hormone-free cream was non-inferior to 0.1% estriol cream for dryness, itching and burning after 43 days; women with severe impact on daily life did better on estriol. The Menopause Society says non-hormone products relieve most mild symptoms.^10,13

Does estriol help multiple sclerosis?

In a phase 2 trial, 164 women on glatiramer acetate had 0.25 versus 0.37 relapses a year with oral estriol 8 mg added (rate ratio 0.63, 95% CI 0.37 to 1.05). The authors said a phase 3 trial is needed to confirm it.¹²

What does bioidentical mean for estriol?

The FDA calls bioidentical a marketing term with no medical or scientific basis when used to imply a benefit. The estriol in UK creams is chemically identical to the body's own, which says nothing about whether a product is safe or effective. A 2021 review calls custom-mixed versions basically unstudied and inconsistently labeled.^1,4,14

Sources

Sources cited on this page

14 sources

1FDA takes action against compounded menopause hormone therapy drugs (news release, January 9, 2008; archived copy)Safety communication U.S. Food and Drug Administration, 2008
2Compounded bioidentical menopausal hormone therapy: ACOG Clinical Consensus No. 6Guideline Obstetrics & Gynecology, 2023 · PMID 37856860
3Estriol 1 mg/g vaginal cream: Summary of Product Characteristics (UK, PL 39699/0058, text revised July 2025)Label Aspen Pharma Trading (via emc), 2025
4Gynest (estriol 0.01% w/w) vaginal cream: Summary of Product Characteristics (UK, PL 23138/0012)Label Marlborough Pharmaceuticals (via emc), 2026
5A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infectionsRCT New England Journal of Medicine, 1993 · PMID 8350884
6Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal womenRCT Clinical Infectious Diseases, 2003 · PMID 12766829
7Efficacy and safety of an ultra-low-dose 0.005% estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopauseRCT Maturitas, 2024 · PMID 39388913
8Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II trialRCT Menopause, 2020 · PMID 32049923
9A phase II randomized trial of the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early breast cancer on an aromatase inhibitorRCT The Oncologist, 2020 · PMID 32459035
10Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: prospective, randomised studyOpen-label trial PLoS One, 2022 · PMID 35551533
11Low-potency oestrogen and risk of endometrial cancer: a case-control studyObservational The Lancet, 1999 · PMID 10359406
12Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trialRCT The Lancet Neurology, 2016 · PMID 26621682
13The 2020 genitourinary syndrome of menopause position statement of The North American Menopause SocietyGuideline Menopause, 2020 · PMID 32852449
14Compounded bioidentical menopausal hormone therapy: a physician perspectiveReview Climacteric, 2021 · PMID 33073628

What changed

Change log

1 entry

Dated changes to this page
Date	Change	Who and why
Oct 23, 2026	Page created: US and UK status by form, UK label and trial doses, combinations with a progestogen, aromatase inhibitors and glatiramer acetate, fertility, monitoring, seven graded studies, side effects, interactions and a trial comparison table.	Writer: Kymata Health EditorialTrigger: Owner request (2026-10-22): hormone library

Kymata Health hormone library. Educational information only; it is not medical advice and does not replace a clinician. Doses are shown as labels and studies print them; a prescriber decides whether and how any hormone is used.